Inimmune raises $22 Million in Series A Funding Led by Two Bear Capital

Jul 09, 2020•about 5 years ago

Amount Raised

$22 Million

Round Type

series a

Missoula

Description

Inimmune, www.inimmune.com, a biotechnology company developing immune therapies and components for more effective vaccines, announced today that it raised $22 million in Series A funding. It was the Missoula-based company's first outside investment. The round was led by Two Bear Capital, www.twobearcapital.com, a new firm based in Whitefish, Montana. Two Bear Capital Founder and Managing Partner Michael Goguen will join Inimmune's board of directors.

Company Information

Company

Inimmune:

Location

Missoula, Montana, United States

About

Inimmune Corp. (Missoula, MT) is a privately held biotechnology company focused on the discovery and development of innovative immunotherapeutics and vaccines. Inimmune is harnessing the human immune system to create safe and effective treatments for allergy, infectious disease, autoimmunity and cancer. Their laboratories and offices are housed in the Montana Technology Enterprise Center (MonTEC) in Missoula.

Related People

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech